Cevostamab (Anti- FcRH5 / IRTA2 / CD307e)

Synonyms: BFCR 4350A; RG 6160; RO 7187797

Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanized IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD.

Cevostamab (Anti- FcRH5 / IRTA2 / CD307e)

Purity & Quality Control

≥99

Biological Activity

Description Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) is a humanized IgG1-based bispecific antibody that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. MW: 145.24 kD.

Product Details

CAS No. 2249888-53-5
Molecular Weight 145.24
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100mMPro-Ac,20mMArg-Ac,pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) | Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) supplier | purchase Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) | Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) cost | Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) manufacturer | order Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) | Cevostamab (Anti- FcRH5 / IRTA2 / CD307e) distributor